Pharmacotherapy of scleritis: current paradigms and future directions

Bibliography

• Smith JR, Mackensen F, Rosenbaum JT. Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol 2007;3:219-26
   PubMedGoogle Scholar
• Raiji VR, Palestine AG, Parver DL. Scleritis and systemic disease association in a community-based referral practice. Am J Ophthalmol 2009;148:946-50
   PubMed Web of Science ®Google Scholar
• Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology 2012;119:43-50
   PubMed Web of Science ®Google Scholar
• Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol 2000;130:469-76
   PubMed Web of Science ®Google Scholar
• Rachitskaya A, Mandelcorn ED, Albini TA. An update on the cause and treatment of scleritis. Curr Opin Ophthalmol 2010;21:463-7
   PubMed Web of Science ®Google Scholar
• Lin P, Bhullar SS, Tessler HH, Goldstein DA. Immunologic markers as potential predictors of systemic autoimmune disease in patients with idiopathic scleritis. Am J Ophthalmol 2008;145:463-71
   PubMed Web of Science ®Google Scholar
• Smith LK, Suhler EB, Lim LL, Possible association between scleritis and lymphoma. Br J Ophthalmol 2007;91:1728-9
   PubMed Web of Science ®Google Scholar
• O'Donoghue E, Lightman S, Tuft S, Watson P. Surgically induced necrotising sclerokeratitis (SINS)–precipitating factors and response to treatment. Br J Ophthalmol 1992;76:17-21
   PubMed Web of Science ®Google Scholar
• McCluskey PJ, Watson PG, Lightman S, Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology 1999;106:2380-6
   PubMed Web of Science ®Google Scholar
• Tittler EH, Nguyen P, Rue KS, Early surgical debridement in the management of infectious scleritis after pterygium excision. J Ophthalmic Inflamm Infect 2012;2:81-7
   PubMedGoogle Scholar
• Lin CP, Shih MH, Tsai MC. Clinical experiences of infectious scleral ulceration: a complication of pterygium operation. Br J Ophthalmol 1997;81:980-3
   PubMed Web of Science ®Google Scholar
• Hodson KL, Galor A, Karp CL, Epidemiology and visual outcomes in patients with infectious scleritis. Cornea 2012;1-7
   PubMed Web of Science ®Google Scholar
• Streho M, Roussat B, Bouaziz T, Bilateral necrotizing scleritis following strabismus surgery for thyroid ophthalmopathy. J Pediatr Ophthalmol Strabismus 2008;45:43-6
   PubMed Web of Science ®Google Scholar
• Rich RM, Smiddy WE, Davis JL. Infectious scleritis after retinal surgery. Am J Ophthalmol 2008;145:695-9
   PubMed Web of Science ®Google Scholar
• Nielsen JS, Blatt S, Perlman JI, Gieser RG. Clinicopathologic case report: scleral buckle associated nontuberculous mycobacterial scleritis. Semin Ophthalmol 2004;19:101-4
   PubMedGoogle Scholar
• Jain V, Garg P, Sharma S. Microbial scleritis-experience from a developing country. Eye (Lond) 2009;23:255-61
   PubMed Web of Science ®Google Scholar
• McMullen M, Kovarik G, Hodge WG. Use of topical steroid therapy in the management of nonnecrotizing anterior scleritis. Can J Ophthalmol 1999;34:217-21
   PubMed Web of Science ®Google Scholar
• Watson PG. The diagnosis and management of scleritis. Ophthalmology 1980;87:716-20
   PubMed Web of Science ®Google Scholar
• Albini TA, Zamir E, Read RW, Evaluation of subconjunctival triamcinolone for nonnecrotizing anterior scleritis. Ophthalmology 2005;112:1814-20
   PubMed Web of Science ®Google Scholar
• Sen HN, Ursea R, Nussenblatt RB, Buggage RR. Subconjunctival corticosteroid injection for the treatment of non-necrotising anterior scleritis. Br J Ophthalmol 2005;89:917-18
   PubMed Web of Science ®Google Scholar
• Sohn EH, Wang R, Read R, Long-term, multicenter evaluation of subconjunctival injection of triamcinolone for non-necrotizing, noninfectious anterior scleritis. Ophthalmology 2011;118:1932-7
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492-513
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Robertson JE Jr. Recognition of posterior scleritis and its treatment with indomethacin. Retina 1993;13:17-21
   PubMed Web of Science ®Google Scholar
• Bauer AM, Fiehn C, Becker MD. Celecoxib, a selective inhibitor of cyclooxygenase 2 for therapy of diffuse anterior scleritis. Am J Ophthalmol 2005;139:1086-9
   PubMed Web of Science ®Google Scholar
• Leese P. Comparison of the effects of etodolac SR and naproxen on gastro-intestinal blood loss. Curr Med Res Opin 1992;13:13-20
   PubMed Web of Science ®Google Scholar
• Sainz de la Maza M, Jabbur NS, Foster CS. An analysis of therapeutic decision for scleritis. Ophthalmology 1993;100:1372-6
   PubMed Web of Science ®Google Scholar
• Elorza B, Elorza MA, Sainz MC, Chantres JR. Analysis of the particle size distribution and internal volume of liposomal preparations. J Pharm Sci 1993;82:1160-3
   PubMed Web of Science ®Google Scholar
• Charkoudian LD, Ying G-S, Thorne JE, Intravenous Pulsed Corticosteroids for Ocular Inflammatory Diseases. Invest Ophthalmol Vis Sci 2010;51:5257
   Web of Science ®Google Scholar
• McCluskey P, Wakefield D. Intravenous pulse methylprednisolone in scleritis. Arch Ophthalmol 1987;105:793-7
   PubMedGoogle Scholar
• Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40
   PubMed Web of Science ®Google Scholar
• Kremer JM. Methotrexate and emerging therapies. Clin Exp Rheumatol 1999;17:S43-6
   PubMed Web of Science ®Google Scholar
• Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008;47:249-55
   PubMed Web of Science ®Google Scholar
• Hemady RK, Baer JC, Foster CS. Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis. Int Ophthalmol Clin 1992;32:241-52
   PubMedGoogle Scholar
• Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005;32:362-5
   PubMed Web of Science ®Google Scholar
• Gangaputra S, Newcomb CW, Liesegang TL, Systemic immunosuppressive therapy for eye diseases Cohort Study. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009;116:2188-98
   PubMed Web of Science ®Google Scholar
• Jachens AW, Chu DS. Retrospective review of methotrexate therapy in the treatment of chronic, noninfectious, nonnecrotizing scleritis. Am J Ophthalmol 2008;145:487-92
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984;311:1528-33
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Kempen JH, Newcomb CW, Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009;148:500-9; e2
   PubMed Web of Science ®Google Scholar
• Galor A, Jabs DA, Leder HA, Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008;115:1826-32
   PubMed Web of Science ®Google Scholar
• Maddocks JL, Lennard L, Amess J, Azathioprine and severe bone marrow depression. Lancet 1986;1:156
   PubMed Web of Science ®Google Scholar
• Lennard L. Therapeutic drug monitoring of cytotoxic drugs. Br J Clin Pharmacol 2001;52(Suppl 1):75S-87S
   PubMed Web of Science ®Google Scholar
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995;345:1321-5
   PubMed Web of Science ®Google Scholar
• Daniel E, Thorne JE, Newcomb CW, Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010;149:423-32; e1-2
   PubMed Web of Science ®Google Scholar
• Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology 2008;115:1416-21; 1421 e1
   PubMed Web of Science ®Google Scholar
• Thorne JE, Jabs DA, Qazi FA, Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005;112:1472-7
   PubMed Web of Science ®Google Scholar
• Lacki JK, Schochat T, Sobieska M, Immunological studies in patients with rheumatoid arthritis treated with methotrexate or cyclophosphamide. Z Rheumatol 1994;53:76-82
   PubMed Web of Science ®Google Scholar
• Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 2002;138:380-4
   PubMed Web of Science ®Google Scholar
• Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cordier JF, Lhote F, A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98
   PubMed Web of Science ®Google Scholar
• Pujari SS, Kempen JH, Newcomb CW, Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010;117:356-65
   PubMed Web of Science ®Google Scholar
• Radis CD, Kahl LE, Baker GL, Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995;38:1120-7
   PubMed Web of Science ®Google Scholar
• Lane L, Tamesis R, Rodriguez A, Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. Ophthalmology 1995;102:1530-5
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Dunn JP, Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480
   PubMedGoogle Scholar
• Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-9
   PubMed Web of Science ®Google Scholar
• Mamo JG. Treatment of Behcet disease with chlorambucil. A follow-up report. Arch Ophthalmol 1976;94:580-3
   PubMed Web of Science ®Google Scholar
• O'Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Med 1984;76:75-84
   PubMed Web of Science ®Google Scholar
• Tessler HH, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br J Ophthalmol 1990;74:353-7
   PubMed Web of Science ®Google Scholar
• Akpek EK, Jabs DA, Tessler HH, Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 2002;109:1506-13
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Fontanilla FA, Kaul S, Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology 2002;109:370-7
   PubMed Web of Science ®Google Scholar
• Suzuki N, Kaneko S, Ichino M, In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506): experience in patients with Behcet's disease. Arthritis Rheum 1997;40:1157-67
   PubMed Web of Science ®Google Scholar
• Fung JJ, Eliasziw M, Todo S, The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 1996;183:117-25
   PubMed Web of Science ®Google Scholar
• Young AL, Wong SM, Leung AT, Successful treatment of surgically induced necrotizing scleritis with tacrolimus. Clin Experiment Ophthalmol 2005;33:98-9
   PubMed Web of Science ®Google Scholar
• Durrani OM, Cameron-Swaby DA, Bowman S, Ainsworth JR. Scleritis as the presenting sign of primary antiphospholipid syndrome. Eye 2001;15:558-9
   PubMed Web of Science ®Google Scholar
• Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc 1998;30:1573-9
   PubMed Web of Science ®Google Scholar
• Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med 2000;2:1-23
   PubMedGoogle Scholar
• Masuda K, Nakajima A, Urayama A, Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989;1:1093-6
   PubMed Web of Science ®Google Scholar
• Kacmaz RO, Kempen JH, Newcomb C, Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010;117:576-84
   PubMed Web of Science ®Google Scholar
• Shimura M, Yasuda K, Fuse N, Effective treatment with topical cyclosporin A of a patient with Cogan syndrome. Ophthalmologica 2000;214:429-32
   PubMed Web of Science ®Google Scholar
• Rosenfeld SI, Kronish JW, Schweitzer WA, Siegal JE. Topical cyclosporine for treating necrotizing scleritis. Arch Ophthalmol 1995;113:20-1
   PubMedGoogle Scholar
• McCarthy JM, Dubord PJ, Chalmers A, Cyclosporine A for the treatment of necrotizing scleritis and corneal melting in patients with rheumatoid arthritis. J Rheumatol 1992;19:1358-61
   PubMed Web of Science ®Google Scholar
• Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev 2003;CD004056
   PubMedGoogle Scholar
• Saw VP, Dart JK, Rauz S, Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 2008;115:253-61; e1
   PubMed Web of Science ®Google Scholar
• Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986;84:527-663
   PubMedGoogle Scholar
• Yoo JH, Chodosh J, Dana R. Relapsing polychondritis: systemic and ocular manifestations, differential diagnosis, management, and prognosis. Semin Ophthalmol 2011;26:261-9
   PubMed Web of Science ®Google Scholar
• Hoang-Xaun T, Foster CS, Rice BA. Scleritis in relapsing polychondritis. Response to therapy. Ophthalmology 1990;97:892-8
   PubMed Web of Science ®Google Scholar
• Wong MH, Su DH, Loh RS. Nodular scleritis and Sweet's syndrome. Clin Experiment Ophthalmol 2007;35:858-60
   PubMed Web of Science ®Google Scholar
• Inamadar AC, Anitha B. HIV-seropositive patient with Sweet's syndrome and nodular scleritis, showing dramatic response after adding dapsone to systemic corticosteroid therapy. Int J Dermatol 2008;47:836-8
   PubMed Web of Science ®Google Scholar
• Naik PM, Lyon GM III, Ramirez A, Dapsone-induced hemolytic anemia in lung allograft recipients. J Heart Lung Transplant 2008;27:1198-202
   PubMed Web of Science ®Google Scholar
• Scallon B, Cai A, Solowski N, Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26
   PubMed Web of Science ®Google Scholar
• Smith JR, Levinson RD, Holland GN, Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252-7
   PubMed Web of Science ®Google Scholar
• Hernandez-Illas M, Tozman E, Fulcher SF, Recombinant human tumor necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye Contact Lens 2004;30:2-5
   PubMedGoogle Scholar
• Taban M, Dupps WJ, Mandell B, Perez VL. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006;14:145-50
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Giampietro C, Gaujoux T, Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol 2012;39:233-9
   PubMed Web of Science ®Google Scholar
• Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol 2006;34:365-74
   PubMed Web of Science ®Google Scholar
• Okada AA, Goto H, Ohno S, Mochizuki M; Ocular Behcet's Disease Research Group Of J. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol 2012;130:592-8
   PubMed Web of Science ®Google Scholar
• Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behcet's disease. Ocul Immunol Inflamm 2012;20:198-202
   PubMed Web of Science ®Google Scholar
• Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm 2012;20:18-26
   PubMed Web of Science ®Google Scholar
• Ardoin SP, Kredich D, Rabinovich E, Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol 2007;144:844-9
   PubMed Web of Science ®Google Scholar
• Gupta SR, Phan IT, Suhler EB. Successful treatment of refractory sympathetic ophthalmia in a child with infliximab. Arch Ophthalmol 2011;129:250-2
   PubMed Web of Science ®Google Scholar
• Wang Y, Gaudio PA. Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm 2008;16:167-71
   PubMed Web of Science ®Google Scholar
• Ahn SJ, Oh JY, Kim MK, Wee WR. Treating refractory scleritis with infliximab. Jpn J Ophthalmol 2009;53:286-7
   PubMed Web of Science ®Google Scholar
• Doctor P, Sultan A, Syed S, Infliximab for the treatment of refractory scleritis. Br J Ophthalmol 2010;94:579-83
   PubMed Web of Science ®Google Scholar
• El-Shabrawi Y, Hermann J. Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis. Eye 2005;19:1017-18
   PubMed Web of Science ®Google Scholar
• Murphy CC, Ayliffe WH, Booth A, Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004;111:352-6
   PubMed Web of Science ®Google Scholar
• Sen HN, Sangave A, Hammel K, Infliximab for the treatment of active scleritis. Can J Ophthalmol 2009;44:e9-e12
   PubMedGoogle Scholar
• Suhler EB, Smith JR, Giles TR, Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009;127:819-22
   PubMed Web of Science ®Google Scholar
• Kaymakcalan Z, Sakorafas P, Bose S, Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009;131:308-16
   PubMed Web of Science ®Google Scholar
• Tynjala P, Kotaniemi K, Lindahl P, Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008;47:339-44
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Rodevand E, Holck P, Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68:696-701
   PubMed Web of Science ®Google Scholar
• Adams AB, Kazim M, Lehman TJ. Treatment of orbital myositis with adalimumab (Humira). J Rheumatol 2005;32:1374-5
   PubMed Web of Science ®Google Scholar
• Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye (Lond) 2007;21:824-5
   PubMed Web of Science ®Google Scholar
• Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol 2010;29:559-61
   PubMed Web of Science ®Google Scholar
• Bawazeer AM, Raffa LH. Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis. Oman J Ophthalmol 2011;4:139-41
   PubMedGoogle Scholar
• Deepak P, Sifuentes H, Sherid M, T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS. with Tumor Necrosis Factor-Alpha (TNF-alpha) Inhibitors: results of the REFURBISH Study. Am J Gastroenterol 2012
   PubMedGoogle Scholar
• Cordero-Coma M, Salom D, Diaz-Llopis M, Golimumab for uveitis. Ophthalmology 2011;118:1892 e3-4
   Web of Science ®Google Scholar
• William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect 2012;2:231-3
   PubMedGoogle Scholar
• Tlucek PS, Stone DU. Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. Cornea 2012;31:90-1
   PubMed Web of Science ®Google Scholar
• Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000;27:79-85
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, E. Ritusimab versus cyclophosphamide for ANCA-Associated vasculitis. N Engl J Med 2010;363:221-32
   PubMed Web of Science ®Google Scholar
• Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010;117:861-9
   PubMed Web of Science ®Google Scholar
• Taylor SR, Salama AD, Joshi L, Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009;60:1540-7
   PubMed Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Vissink A, Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M, Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010;13:246-52
   PubMed Web of Science ®Google Scholar
• Iaccheri B, Androudi S, Bocci EB, Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm 2010;18:223-5
   PubMed Web of Science ®Google Scholar
• Chauhan S, Kamal A, Thompson RN, Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol 2009;93:984-5
   PubMed Web of Science ®Google Scholar
• Ahmadi-Simab K, Lamprecht P, Nolle B, Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 2005;64:1087-8
   PubMed Web of Science ®Google Scholar
• Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005;89:1542
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, Yavuz S. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocul Immunol Inflamm 2008;16:230-2
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Pontikaki I, Modorati G, Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 2011;11:35-9
   PubMed Web of Science ®Google Scholar
• Butler NJ, Lim LL, Giles TR, Rituximab in the treatment of refactory scleritis and non-infectious orbital inflammation: 24 week outcomes from a phaseI/II prospective, randomized study. Invest Ophthalmol Vis Sci 2011
   Web of Science ®Google Scholar
• Yang H, Wang J, Du J, Structural basis of immunosuppression by the therapeutic antibody daclizumab. Cell Res 2010;20:1361-71
   PubMed Web of Science ®Google Scholar
• Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003;110:786-9
   PubMed Web of Science ®Google Scholar
• Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 2003;42:1539-44
   PubMed Web of Science ®Google Scholar
• Isaacs JD, Hale G, Waldmann H, Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. Br J Ophthalmol 1995;79:1054-5
   PubMed Web of Science ®Google Scholar
• Wertheim MS, Ross AH, Tole DM. The use of Campath in severe peripheral ulcerative keratitis associated with Wegener's granulomatosis. Eye (Lond) 2006;20:1453-4
   PubMed Web of Science ®Google Scholar
• Dick AD, Meyer P, James T, Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000;84:107-9
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Tesser J, Schiff M, Safety of extended treatment with anakinra in pateints with rheumatoid arthritis. Ann Rheum Dis 2006; In press
   Google Scholar
• Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609-32
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 2012;39:1294-5
   PubMed Web of Science ®Google Scholar
• Muselier A, Bielefeld P, Bidot S, Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 2011;19:382-3
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23
   PubMed Web of Science ®Google Scholar
• Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol 2008;35:1897-8
   PubMed Web of Science ®Google Scholar
• Kenawy N, Cleary G, Mewar D, Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2011;249:297-300
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Tesser J, Schiff MH, Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1006-12
   PubMed Web of Science ®Google Scholar
• Teoh SC, Sharma S, Hogan A, Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 2007;91:263-4
   PubMed Web of Science ®Google Scholar
• Planck SR, Woods A, Clowers JS, Impact of IL-1 signalling on experimental uveitis and arthritis. Ann Rheum Dis 2012;71:753-60
   PubMed Web of Science ®Google Scholar
• Cohen AE, Assang C, Patane MA, Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis. Ophthalmology 2012;119:66-73
   PubMed Web of Science ®Google Scholar